The analysis included a range of RCTs and observational studies, which provided valuable insights into the effects of SGLT2 inhibitors on major CVDs, such as myocardial infarction, myocardial ischemia, stroke, and cardiovascular death. Here, SLC5A2 is linked to myocardial ischemia.